Novo Nordisk to affirm superiority of CagriSema in obesity market
WEBNov 23, 2023 · Therefore, Novo Nordisk has set out to challenge Eli Lilly’s therapy to affirm its superiority prior to regulatory approval, according to data and analytics company GlobalData. is predicted to reach $37.06 billion in 2031, with 70.9% of the to be dominated by GLP-1R agonists, GlobalData reveals. The potential of GLP-1RAs within the obesity ...
The top 5 CDMOs developing advanced therapies
WEBJul 18, 2024 · WuXi Advanced Therapies is a CDMO arm of WuXi AppTec. The larger company originated as the drug development service provider and gradually expanded its offerings over the years, with the acquisition of AppTec Laboratory Services leading to the new name of WuXi Apptec. WuXi Advanced Therapies, also known as WuXi ATU, focuses on the development ...
Building a biotech hub: Switzerland focuses on mRNA, CGT and …
WEBSep 8, 2021 · There are 314 biotech companies in Switzerland: broken down into 251 developers and 63 suppliers. Swiss life science exports were valued at CHF 99.1bn ($108bn USD) in 2020 and accounted for 44% of total exports. The sector has grown by a factor of 4.5 since 2000, when life sciences accounted for 17% of …
Touchlight secures $2.4m to prove pandemic potential of …
WEBNov 29, 2022 · Touchlight has secured a grant from the Bill & Melinda Gates Foundation for a research program aimed at demonstrating that its enzymatically produced novel DNA format can support a rapid, scalable, durable, and thermostable vaccine solution for future pandemics, particularly in low and middle income countries. The …
GE Healthcare Life Sciences completes transition into Cytiva
WEBApr 1, 2020 · Now, with the deal complete, GE Healthcare Life Sciences has emerged at the other side rebranded as Cytiva. The company will retain the same staff, which means that it will have 7,000 employees and possess operations in 40 countries, becoming part of Danaher Corporation Life Sciences platform. CEO and president of Cytiva, Emmanuel Ligner, spoke ...
BioNTech starts building mRNA vaccine manufacturing facility in …
WEBJun 28, 2022 · News and analysis on the clinical development and manufacture of large molecule drugs. Construction works on an mRNA manufacturing facility have started in Kigali, Rwanda: as BioNTech works to create a pan-African end-to-end manufacturing network for mRNA-based vaccines. The Rwandan facility, which will be around 30,000 square meters in size ...
AGC Biologics starts construction at new Copenhagen facility
WEBAug 20, 2021 · CDMO AGC Biologics has announced the groundbreaking of a new multipurpose facility in Copenhagen, Denmark. The expansion will allow AGC Biologics to generate around 250-300 new workplaces in Denmark. The production will be based on genetically modified organisms, biosafety level 1, manufactured with …
Aragen launches $30 million biologics manufacturing facility
WEBNov 2, 2023 · News and analysis on the clinical development and manufacture of large molecule drugs. The Indian contract research development and manufacturing organization (CRDMO) Aragen Life Sciences will invest $30 million in building a 160,000 square-meter biologics manufacturing facility in Bangalore. The upcoming Indian facility will be used to …
Eden Biologics finalizes sale of CDMO assets to Bora
WEBJul 18, 2022 · Eden Biologics reports that it has completed the divestment of its CDMO business assets to Bora Pharmaceuticals. Eden and Bora entered into a definitive agreement in May this year to enable Eden’s CDMO assets to be acquired by an entity wholly owned by Bora in a cash deal valued at no less than US$50m and up to US$65m if certain milestones ...
About us
WEBAbout the publisher. We are William Reed , the specialist B2B media, business intelligence and events group dedicated to helping businesses succeed.. Our diverse portfolio of category-leading brands serves a global audience of almost 5M monthly users, supported by sector-specific insights & research, up-to-the-minute digital media and cutting-edge customer solutions.